Rosemary Young

1.3k total citations · 1 hit paper
15 papers, 1.0k citations indexed

About

Rosemary Young is a scholar working on Oncology, Hematology and Cancer Research. According to data from OpenAlex, Rosemary Young has authored 15 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Hematology and 4 papers in Cancer Research. Recurrent topics in Rosemary Young's work include Acute Myeloid Leukemia Research (3 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Hematopoietic Stem Cell Transplantation (3 papers). Rosemary Young is often cited by papers focused on Acute Myeloid Leukemia Research (3 papers), Pancreatic and Hepatic Oncology Research (3 papers) and Hematopoietic Stem Cell Transplantation (3 papers). Rosemary Young collaborates with scholars based in United Kingdom, Australia and United States. Rosemary Young's co-authors include J.H. Scarffe, Alfredo Romano, Javier Sastre, Werner Scheithauer, Josep Tabernero, Giampaolo Tortora, Luís Teixeira, Volker Heinemann, Volker Kunzmann and Daniel D. Von Hoff and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Rosemary Young

15 papers receiving 1.0k citations

Hit Papers

nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic... 2015 2026 2018 2022 2015 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
    2015 504 citations David Goldstein, Robert H. El-Maraghi et al. JNCI Journal of the National Cancer Institute profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rosemary Young United Kingdom 10 695 241 226 199 194 15 1.0k
Silvia Brugnatelli Italy 22 635 0.9× 338 1.4× 531 2.3× 219 1.1× 204 1.1× 78 1.4k
Peter Kozuch United States 19 557 0.8× 176 0.7× 259 1.1× 263 1.3× 117 0.6× 42 1.1k
Cherie Perez United States 9 314 0.5× 187 0.8× 419 1.9× 198 1.0× 149 0.8× 16 955
Rangaswamy Govindarajan United States 12 430 0.6× 170 0.7× 427 1.9× 130 0.7× 189 1.0× 39 973
Lucien Perey Switzerland 18 444 0.6× 116 0.5× 321 1.4× 157 0.8× 117 0.6× 43 878
Gennaro Gadaleta‐Caldarola Italy 19 406 0.6× 118 0.5× 312 1.4× 261 1.3× 189 1.0× 51 1.0k
Steven Blotner United States 17 598 0.9× 118 0.5× 257 1.1× 223 1.1× 177 0.9× 36 1.1k
Preston D. Steen United States 18 579 0.8× 79 0.3× 259 1.1× 329 1.7× 129 0.7× 47 1.0k
Martine George United States 9 277 0.4× 179 0.7× 120 0.5× 298 1.5× 101 0.5× 16 898
Joo Han Lim South Korea 18 393 0.6× 72 0.3× 335 1.5× 144 0.7× 163 0.8× 61 867

Countries citing papers authored by Rosemary Young

Since Specialization
Citations

This map shows the geographic impact of Rosemary Young's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rosemary Young with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rosemary Young more than expected).

Fields of papers citing papers by Rosemary Young

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rosemary Young. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rosemary Young. The network helps show where Rosemary Young may publish in the future.

Co-authorship network of co-authors of Rosemary Young

This figure shows the co-authorship network connecting the top 25 collaborators of Rosemary Young. A scholar is included among the top collaborators of Rosemary Young based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rosemary Young. Rosemary Young is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Young, Rosemary, Paul N. Mainwaring, Philip Clingan, et al.. (2018). nab‐Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial. Asia-Pacific Journal of Clinical Oncology. 14(5). e325–e331. 4 indexed citations
2.
Tebbutt, Niall C., Timothy Price, Nicole Wong, et al.. (2016). Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. British Journal of Cancer. 114(5). 505–509. 40 indexed citations
3.
Goldstein, David, Robert H. El-Maraghi, Pascal Hammel, et al.. (2015). nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. JNCI Journal of the National Cancer Institute. 107(2). dju413–dju413. 504 indexed citations breakdown →
4.
Goldstein, David, Pascal Hammel, Volker Heinemann, et al.. (2014). Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas.. Journal of Clinical Oncology. 32(3_suppl). 178–178. 27 indexed citations
5.
Tebbutt, Niall C., Timothy Price, Katrin Marie Sjoquist, et al.. (2013). Final results of AGITG ATTAX3 study: Randomized phase II study of weekly docetaxel (T), cisplatin, and fluoropyrimidine (F) with or without panitumumab (P) in advanced esophagogastric (OG) cancer.. Journal of Clinical Oncology. 31(15_suppl). 4081–4081. 4 indexed citations
6.
Nott, Louise, et al.. (2008). Hyperammonaemic encephalopathy associated with rituximab‐containing chemotherapy. Internal Medicine Journal. 38(10). 800–803. 9 indexed citations
7.
Young, Rosemary, Malcolm Ranson, James Chang, et al.. (1997). Phase II trial of rhIL-6 (Interleukin-6) prior to and concurrently with VAD (vincristine, doxorubicin and dexamethasone) chemotherapy for patients with multiple myeloma. European Journal of Cancer. 33(2). 307–311. 2 indexed citations
8.
Anderson, Heather, J.H. Scarffe, Malcolm Ranson, et al.. (1995). VAD chemotherapy as remission induction for multiple myeloma. British Journal of Cancer. 71(2). 326–330. 69 indexed citations
9.
Jayson, Gordon C., D Crowther, J Prendiville, et al.. (1995). A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion. British Journal of Cancer. 72(2). 461–468. 113 indexed citations
10.
Pettengell, Ruth, Thomas Luft, L. H. Coutinho, et al.. (1995). Effects of interleukin‐6 on mobilization of primitive haemopoietic cells into the circulation. British Journal of Haematology. 89(2). 237–242. 17 indexed citations
11.
12.
Pettengell, Ruth, GR Morgenstern, Penella J. Woll, et al.. (1993). Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood. 82(12). 3770–3777. 152 indexed citations
13.
Pettengell, Ruth, GR Morgenstern, Penella J. Woll, et al.. (1993). Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. Blood. 82(12). 3770–3777. 13 indexed citations
14.
Vanderhoof, Jon A., et al.. (1993). Treatment of Cyclic Vomiting in Childhood with Erythromycin. Journal of Pediatric Gastroenterology and Nutrition. 17(4). 387–391. 47 indexed citations
15.
Vanderhoof, Jon A., et al.. (1993). Treatment of Cyclic Vomiting in Childhood with Erythromycin. Journal of Pediatric Gastroenterology and Nutrition. 17(4). 387–391. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Silvia Brugnatelli Breakdown of academic impact, for papers by Peter Kozuch Breakdown of academic impact, for papers by Cherie Perez Breakdown of academic impact, for papers by Rangaswamy Govindarajan Breakdown of academic impact, for papers by Lucien Perey Breakdown of academic impact, for papers by Gennaro Gadaleta‐Caldarola Breakdown of academic impact, for papers by Steven Blotner Breakdown of academic impact, for papers by Preston D. Steen Breakdown of academic impact, for papers by Martine George Breakdown of academic impact, for papers by Joo Han Lim
Rankless by CCL
2026